Skip to main content
. 2023 Sep 18;24(9):253. doi: 10.31083/j.rcm2409253

Table 1.

Baseline information after inverse-probability-weighted among MVR and AVR cohorts.

Mitral-valve replacement Aortic-valve replacement
Bioprosthetic Mechanical SMD Bioprosthetic Mechanical SMD
(n = 1215.0) (n = 1176.5) (n = 455.4) (n = 455.7)
Age, yrs (mean (SD)) 56.66 (5.37) 57.04 (4.98) 0.074 58.55 (6.03) 58.78 (5.73) 0.040
Female, n (%) 837.9 (69.0) 824.5 (70.1) 0.024 126.6 (27.8) 161.8 (35.5) 0.166
BMI (mean (SD)) 23.50 (3.16) 23.53 (3.38) 0.011 24.63 (3.31) 24.45 (3.29) 0.055
Hypertension, n (%) 126.7 (10.4) 128.8 (10.9) 0.017 133.0 (29.2) 136.2 (29.9) 0.015
Hyperlipidemia, n (%) 40.7 (3.3) 38.6 (3.3) 0.004 0.0 (0.0) 9.0 (2.0) 0.200
Diabetes, n (%) 68.4 (5.6) 67.1 (5.7) 0.003 22.6 (5.0) 20.8 (4.6) 0.018
Stroke, n (%) 57.3 (4.7) 52.5 (4.5) 0.012 3.3 (0.7) 5.4 (1.2) 0.046
COPD, n (%) 71.9 (5.9) 90.6 (7.7) 0.071 38.6 (8.5) 29.8 (6.5) 0.073
PVD, n (%) 0.0 (0.0) 7.0 (0.6) 0.109 1.0 (0.2) 0.0 (0.0) 0.066
Infective endocarditis, n (%) 8.4 (0.7) 8.5 (0.7) 0.004 5.5 (1.2) 7.2 (1.6) 0.033
Atrial fibrillation, n (%) 912.8 (75.1) 884.1 (75.1) <0.001 35.6 (7.8) 40.3 (8.8) 0.037
Coronary heart disease, n (%) 11.0 (0.9) 15.5 (1.3) 0.039 11.5 (2.5) 14.0 (3.1) 0.033
NYHA class, n (%) 0.168 0.123
I 67.4 (5.5) 29.9 (2.5) 22.5 (4.9) 21.7 (4.8)
II 738.2 (60.8) 711.6 (60.5) 313.2 (68.8) 294.8 (64.7)
III 383.6 (31.6) 397.2 (33.8) 111.9 (24.6) 124.4 (27.3)
IV 25.8 (2.1) 37.8 (3.2) 7.7 (1.7) 14.7 (3.2)
Liver disease, n (%) 2.6 (0.2) 3.2 (0.3) 0.011 0.0 (0.0) 1.0 (0.2) 0.066
Previous PCI, n (%) 1.0 (0.1) 0.0 (0.0) 0.041 3.2 (0.7) 2.2 (0.5) 0.027

Note: AVR, aortic valve replacement; MVR, mitral valve replacement; BMI, body mass index; COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; SMD, standardized mean difference.